Abnormal cervical screening / cervical dysplasia / abnormal cervix
Adult

Gynaecology
HealthPathways

Get localised health information, at the point of care.
Sign in to HealthPathways

Useful Management Information

  • A single Cervical Screening Test may be considered for women between the ages of 20 and 24 years who experienced their first sexual activity at a young age (e.g., before 14 years) or who had not received the HPV vaccine before sexual activity commenced.
  • Adolescent patients with abnormal HPV should follow the same pathway as adult patients. Patients <25 years old should also have screening for STI as they are a high-risk group.
    • Consider using oestrogen cream in post-menopausal patients
  • Patients with positive non-16/18 but normal or LSIL on LBC would not need referral and only a repeat CST in 12 months.
  • Recall women in 6-12 weeks if they have an unsatisfactory screening report.
  • Specific efforts should be made to provide screening for Aboriginal and Torres Strait Islander women. They should be invited and encouraged to participate in the NCSP and have a 5-yearly HPV test, as recommended for all Australian women.
  • Women who have been treated for HSIL (CIN2/3) do not need a post-treatment colposcopy. These women should have a co-test (HPV and LBC test) performed at 12 months after treatment, and annually thereafter, until she receives a negative co-test on two consecutive occasions, when she can return to routine 5 yearly screening. This is called ‘test of cure’.
  • If, at any time post treatment, the woman has a positive oncogenic HPV (16/18) test result, she should be referred for colposcopic assessment (regardless of the reflex LBC result).
  • If, at any time during Test of Cure, the woman has a LBC prediction of pHSIL/HSIL or any glandular abnormality, irrespective of HPV status, she should be referred for colposcopic assessment.

Clinical Resources

Minimum Referral Criteria

Does your patient meet the minimum referral criteria?
Category 1 (appointment within 30 calendar days)
  • Invasive cancer (squamous, glandular, other). For optimum care, patient should be seen by gynaecological oncology (National guidelines suggests being seen at the earliest opportunity for urgent
    evaluation)
  • LBC of PHSIL/HSIL
  • Positive HPV 16/18 and
    • unknown cytology
    • unsatisfactory LBC
    • previous treatment for PHSIL/HSIL (National guidelines suggests
      being seen at the earliest opportunity, ideally within 8 weeks)
    • past history of positive HPV 16/18 (National guidelines suggests
      being seen at the earliest opportunity, ideally within 8 weeks)
    • Atypical glandular cells/endocervical cells of undetermined significance
  • Positive HPV non 16/18 and
    • Atypical glandular cells/endocervical cells of undetermined significance

Glandular lesions

  • AIS or possible high grade glandular lesion
  • any atypical glandular cells/endocervical cells of undetermined
    significance
Category 2 (appointment within 90 calendar days)
  • Positive HPV 16/18 and
    • normal LBC
    • PLSIL/LSIL
  • Positive HPV non 16/18 and
    • Persistant positive non 16/18 HPV or HPV other
    • on 3 consecutive yearly test or
    • in a person who is:
      • two or more years overdue for screening at the time of the initial screen
      • identifies as Aboriginal or Torres Strait Islander
      • aged 50-69 years
    • women aged 70+
    • immune deficient women
    • women currently undergoing Test of Cure following treatment of histological HSIL
  • History of diethylstilboestrol (DES) exposure in utero regardless of HPV status or LBC test
  • Abnormal appearing cervix with normal cervical screening
  • Recurrent post-coital bleeding in pre-menopausal woman after STI excluded/treated – gynaecological assessment recommended
  • Any episode of unexplained vaginal bleeding (including post-coital) in a post-menopausal woman
  • Unexplained persistent unusual vaginal discharge, especially if offensive and blood stained and after STI excluded/treated
  • Any abnormal result and past history of excisional treatment of AIS
Category 3 (appointment within 365 calendar days)
  • No category 3 criteria
  • If the patient does not meet the criteria for referral but the referring practitioner believes the patient requires specialist review, a clinical override may be requested:
    • Please explain why (e.g. warning signs or symptoms, clinical modifiers, uncertain about diagnosis, etc.)
  • Please note that your referral may not be accepted or may be redirected to another service.

Essential Referral Information

  • History of:
    • any abnormal bleeding (i.e. post-coital and intermenstrual) or abnormal discharge
    • previous abnormal cervical screening results and any treatment
    • immunosuppressive therapy
  • Medical management to date
  • Most recent or current cervical screening results (LBC should be performed on any sample with positive oncogenic HPV)

If a specific test result cannot be obtained due to access, financial, religious, cultural or consent reasons a clinical override may be requested. This reason must be clearly articulated in the body of the referral.

Additional Referral Information

  • BMI
  • HPV vaccination history
  • STI screen result - endocervical swab or first catch urine for chlamydia +/- gonorrhoea NAA
  • History of smoking
Last updated 13 March 2024

Send Referrals To

Smart Referrals

Preferred Method
About Smart Referrals

Secure Web Transfer

Send to: Gold Coast Health Service District

Internal Referrals

Gynaecology (E-Blueslips)
Colposcopy (E-Blueslips)

Fax

(07) 5687 4497

Post

Booking and Referral Centre
Gold Coast University Hospital
1 Hospital Boulevard
Southport QLD 4215

Enquiries

1300 559 083

Related HealthPathways

No directly related pathways found

Service Availability

Dr Graeme Walker
Medical Director Gynaecology

Facilities

Gold Coast University Hospital
Robina Hospital

If you would like to send a named referral, please address it to the specialist listed above, who will allocate a suitably qualified specialist to see the patient. Alternatively, you can view a full list of our specialists.

Gold Coast Health - For Clinicians
© The State of Queensland 1995-2021 | Queensland Government
Queensland Government acknowledges the Traditional Owners of the land and pays respect to Elders past, present and future.